CRVO CervoMed Inc.

Nasdaq www.cervomed.com


$ 7.77 $ 0.25 (3.36 %)    

Thursday, 13-Nov-2025 12:06:48 EST
QQQ $ 611.72 $ -5.96 (-0.96 %)
DIA $ 478.46 $ -2.92 (-0.61 %)
SPY $ 675.87 $ -4.61 (-0.68 %)
TLT $ 89.83 $ 0.03 (0.03 %)
GLD $ 386.58 $ -0.70 (-0.18 %)
$ 7.405
$ 7.45
$ 7.71 x 40
$ 7.83 x 300
$ 7.51 - $ 7.70
$ 1.80 - $ 16.94
54,993
na
68.52M
$ -0.17
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-07-2025 09-30-2025 10-Q
2 08-08-2025 06-30-2025 10-Q
3 05-12-2025 03-31-2025 10-Q
4 03-17-2025 12-31-2024 10-K
5 11-12-2024 09-30-2024 10-Q
6 08-09-2024 06-30-2024 10-Q
7 05-14-2024 03-31-2024 10-Q
8 03-29-2024 12-31-2023 10-K
9 11-13-2023 09-30-2023 10-Q
10 08-08-2023 06-30-2023 10-Q
11 05-15-2023 03-31-2023 10-Q
12 03-24-2023 12-31-2022 10-K
13 11-14-2022 09-30-2022 10-Q
14 08-12-2022 06-30-2022 10-Q
15 05-12-2022 03-31-2022 10-Q
16 03-18-2022 12-31-2021 10-K
17 11-10-2021 09-30-2021 10-Q
18 08-11-2021 06-30-2021 10-Q
19 05-07-2021 03-31-2021 10-Q
20 03-17-2021 12-31-2020 10-K
21 11-12-2020 09-30-2020 10-Q
22 08-07-2020 06-30-2020 10-Q
23 05-11-2020 03-31-2020 10-Q
24 03-17-2020 12-31-2019 10-K
25 11-08-2019 09-30-2019 10-Q
26 08-08-2019 06-30-2019 10-Q
27 05-09-2019 03-31-2019 10-Q
28 03-19-2019 12-31-2018 10-K
29 11-13-2018 09-30-2018 10-Q
30 08-10-2018 06-30-2018 10-Q
31 05-10-2018 03-31-2018 10-Q
32 04-02-2018 12-31-2017 10-K
33 11-13-2017 09-30-2017 10-Q
34 08-14-2017 06-30-2017 10-Q
35 05-15-2017 03-31-2017 10-Q
36 03-31-2017 12-31-2016 10-K
37 11-14-2016 09-30-2016 10-Q
38 08-15-2016 06-30-2016 10-Q
39 05-16-2016 03-31-2016 10-Q
40 03-25-2016 12-31-2015 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 d-boral-capital-maintains-buy-on-cervomed-maintains-31-price-target

D. Boral Capital analyst Jason Kolbert maintains CervoMed (NASDAQ:CRVO) with a Buy and maintains $31 price target.

 cervomed-q3-eps-084-misses-049-estimate-sales-322569k-miss-1300m-estimate

CervoMed (NASDAQ:CRVO) reported quarterly losses of $(0.84) per share which missed the analyst consensus estimate of $(0.49) by...

 hc-wainwright--co-upgrades-cervomed-to-buy-raises-price-target-to-25

HC Wainwright & Co. analyst Raghuram Selvaraju upgrades CervoMed (NASDAQ:CRVO) from Neutral to Buy and raises the price ...

 d-boral-capital-maintains-buy-on-cervomed-maintains-31-price-target

D. Boral Capital analyst Jason Kolbert maintains CervoMed (NASDAQ:CRVO) with a Buy and maintains $31 price target.

 cervomed-drug-cut-dementia-progression-risk-by-75-in-trial

CervoMed's Phase 2b trial shows neflamapimod reduces dementia progression and plasma GFAP, with significant cognitive impro...

 cervomed-shares-additional-data-from-phase-2b-rewind-lb-trial-further-demonstrating-neflamapimods-potential-for-dementia-with-lewy-bodies

Significant improvement relative to placebo on primary outcome measure, change in Clinical Dementia Rating Sum of Boxes (CDR-SB...

 cervomed-highlights-dementia-drug-results-at-major-neurology-conference

CervoMed Inc. (NASDAQ:CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders (Ce...

 hc-wainwright--co-reiterates-neutral-on-cervomed-announces-11-price-target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates CervoMed (NASDAQ:CRVO) with a Neutral and announces $11 price ...

 d-boral-capital-maintains-buy-on-cervomed-raises-price-target-to-31

D. Boral Capital analyst Jason Kolbert maintains CervoMed (NASDAQ:CRVO) with a Buy and raises the price target from $15 to $31.

 roth-capital-reiterates-buy-on-cervomed-lowers-price-target-to-16

Roth Capital analyst Boobalan Pachaiyappan reiterates CervoMed (NASDAQ:CRVO) with a Buy and lowers the price target from $20...

 chardan-capital-maintains-buy-on-cervomed-maintains-15-price-target

Chardan Capital analyst Daniil Gataulin maintains CervoMed (NASDAQ:CRVO) with a Buy and maintains $15 price target.

 cervomed-q2-eps-070-misses-063-estimate-sales-1758m-beat-1734m-estimate

CervoMed (NASDAQ:CRVO) reported quarterly losses of $(0.70) per share which missed the analyst consensus estimate of $(0.63) by...

 canaccord-genuity-maintains-buy-on-cervomed-raises-price-target-to-27

Canaccord Genuity analyst Sumant Kulkarni maintains CervoMed (NASDAQ:CRVO) with a Buy and raises the price target from $21 t...

 cervomeds-dementia-data-show-slowed-disease-progression

CervoMed reports 32-week data showing neflamapimod slowed DLB progression and reduced neurodegeneration biomarkers with good to...

 d-boral-capital-maintains-buy-on-cervomed-maintains-10-price-target

D. Boral Capital analyst Jason Kolbert maintains CervoMed (NASDAQ:CRVO) with a Buy and maintains $10 price target.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION